{"id":7853,"date":"2023-09-19T09:13:59","date_gmt":"2023-09-19T09:13:59","guid":{"rendered":"https:\/\/www.patientbloodmanagement.de\/?page_id=7853"},"modified":"2024-02-16T16:33:07","modified_gmt":"2024-02-16T16:33:07","slug":"alice","status":"publish","type":"page","link":"https:\/\/www.patientbloodmanagement.de\/en\/alice\/","title":{"rendered":"ALICE"},"content":{"rendered":"
\"\"<\/div>\n

Background<\/h2>\n

Preoperative anaemia is common in surgery, with a prevalence between 10 and 50 %, and is an independent risk factor for morbidity and mortality. Due to the potential risk of additional blood loss, anaemia represents a serious disease condition within the surgical field. Especially patients undergoing major elective surgery are at risk of substantial blood loss. Anaemia is mostly the result of an inadequate erythropoiesis due to iron deficiency, lack of vitamin B12 or folate, and bone marrow diseases. Among the elderly, renal disease and chronic inflammation account for approximately one-third of all anaemia incidences. The aim of this study is to provide detailed data about the prevalence of preoperative deficiencies in iron, vitamin B12 and\/or folate and the presence of underlying renal or chronic diseases in patients undergoing major surgery. Results will facilitate design of supplementation strategies to improve haemoglobin level before surgery.<\/p>\n

Objectives<\/h2>\n

The main objective of ALICE is to estimate the prevalence of preoperative anaemia and subtypes (anaemia caused by deficiency in iron, vitamin B12 and\/or folate, and renal or chronic disease) in patients undergoing major surgery. A secondary objective is the assessment of the association of preoperative anaemia and subtypes with in-hospital morbidity and mortality accounting for other predictive factors (e.g. age, surgical discipline).<\/p>\n

Study design<\/h2>\n

ALICE is a worldwide multicentre, prospective observational study.
\nRecruitment period: 1 week<\/p>\n

\"\"<\/div>\n

Inclusion criteria<\/h2>\n

\u2022 Age \u2265 18 years
\n\u2022 Written informed consent prior to study participating according to the national law requirements
\n\u2022 Patients undergoing major surgery
\n\u2022 Expected hospital stay with a minimum of 24 hours<\/p>\n

Exclusion criteria<\/h2>\n

\u2022 Preoperative autologous blood donation
\n\u2022 Patients with expected re-surgery within the planned 7-day recruitment period<\/p>\n

Recording of endpoints<\/h2>\n

All data will be collected and there will be no study-related interventions.<\/p>\n\n\n\n\n
\n
RECRUITED HOSPITALS<\/h6>\n<\/td>\n
\n
SCHEDULED SURGICAL PATIENTS<\/span><\/h6>\n<\/td>\n<\/tr>\n
\"\"<\/td>\n\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/h3>\n

Newsletter<\/span><\/h2>\n

Here is our 14th newsletter -> ALICE-Newsletter_#14<\/a>
\nHere is our 13th newsletter -> ALICE-Newsletter_#13<\/a><\/p>\n

Last patient in: Decembre 2021<\/strong>!!!<\/strong><\/p>\n

End of study period: March 2022!!!<\/strong><\/p>\n

Here is our 12th newsletter ->\u00a0ALICE-Newsletter_#12<\/a>
\nHere is our 11th newsletter ->\u00a0ALICE-Newsletter_#11<\/a>
\nHere is our 10th newsletter ->\u00a0ALICE-Newsletter_#10<\/a>
\nHere is our 9th newsletter\u00a0 \u00a0-> ALICE-Newsletter_#9<\/a>
\nHere is our 8h newsletter\u00a0 \u00a0 -> ALICE-Newsletter_#8<\/a><\/p>\n

Since July 2021, 3 hospitals recruited patients and another 4 hospitals are starting patient recruitment this week:
\nDr Wiesenack from Ev. Diakoniekrankenhaus Germany
\nDr Hamid from East Nile Hospital Sudan
\nDr Daper from CHU Charleroi Belgium
\nDr Wittmann from University Hospital Bonn Germany
\nDr Reichmayr from Klinik Floridsdorf Austria
\nDr Gomez Lopez from Hospital de Medina del Campo Spain
\nDr Gibbs from University of Cape Town and Groote Schuur Hospital South Africa
\nThank you very much for your commitmemt and support<\/strong><\/p>\n